

DAFTAR PUSTAKA

1. Maragakis LL, Perl MT. *Acinetobacter baumannii*: Epidemiology, Antimicrobial Resistance, and Treatment Options. *Clin Infect Dis*. 2008;46:1254-63.
2. Moehario LK, Tjoa E, Kiranasari A, Ningsih I, Rosana Y, Kurniawati A. Trends in antimicrobial susceptibility of gram-negative bacteria isolated from blood in Jakarta from 2002 to 2008. *J Infect Dev Ctries* 2009;3(11):838-43.
3. Pollack A. Rising Treat of Infection Unfazed by Antibiotics. *NYT*.2010;114:117-25.
4. Hidron AI, Edwards JR, Patel J. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2008;29:996-1011.
5. Bergogne-berezin E, Towner KJ. *Acinetobacter spp.* as nosocomial pathogens: microbiological, clinical, and epidemiological features. *CMR*. 2008;9:148-65.
6. Silma B. Faktor risiko dan pengaruh klinis infeksi Carbapanem-resistant *Acinetobacter sp* di RSUP DR.Kariadi Semarang. *UEJS*.2011:10-3.
7. Frasca D, Fizelier CD, Mimoz O. Prevention of central venous catheter related infection in the intensive care unit. *Crit Care*. 2010;14:2-8.
8. Poirel L, Bonnin RA, Nordmann P.Genetic basis of antibiotic resistance in pathogenic *Acinetobacter* species. *IUBMB Life*.2011;63(12):1061-7.
9. Mayasari E, Siregar C. Prevalence of *A. baumannii* isolated from clinical specimens in Adam Malik Hospital. *MKA*.2014;37(1):2-5.
10. Gustawan I.W, Satari H.I, Amir I, Astrawinata DAW. Gambaran Infeksi *A. baumannii* dan Pola Sensitifitasnya terhadap Antibiotik. *Sari Pediatri*.2014;16(1):38-9.
11. Peleg AY, Seifert H, Paterson DL. *A. baumannii*: emergence of a successful pathogen. *Clin Microbiol Rev*.2008;21:538-2.
12. Azimi L,Talebi M, Pourshafie MR, Owlia P, Rastegar LA. Characterization of carbapenemases in extensively drug resistance *A. baumannii* in a burn care center in Iran.*Int J Mol Cell Med*.2015;4(1):46-53.
13. Kementrian Kesehatan RI. Pedoman Pencegahan dan Pengendalian Infeksi di Rumah sakit dan Fasilitas Pelayanan Kesehatan Lainnya.2011. [Online] <http://www.depkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/profil-kesehatan-indonesia-2011.pdf>. Diakses pada 14 januari 2019.
14. WHO. Prevention of hospital-acquired infections. 2002.[Online] <http://www.who.int/csr/resources/publications/drugresist/en/>.Diakses pada 16 Desember 2018.
15. Nissa A. Identifikasi bakteri patogen pada tombol lift di RSUP Dr. M. Djamil Padang [skripsi]. Padang: Fakultas Kedokteran Unand.2016.
16. Soedarto S. *Acinetobacter*. In: Mariyam, Soedarto S. Infeksi Nosokomial di Rumah Sakit. Jakarta : Sagung Seto;2016.h.2-35.
17. Villegas MV, Hartstein AI. *Acinetobacter* outbreaks, 1977-2000.*Infect Control Hosp Epidemiol*.2003;24(4):284-95.

18. Coelho J, Woodford N, Turton J & Livermore D M. Multiresistant *Acinetobacter* in the UK: how big a threat?. *Journal of Hospital Infections*.2004;58:167–9 .
19. Ghandam NR, Gupta N, Jadhav SV, Misra RN. Isolation of *A. baumannii* from cerebrospinal fluid following craniotomy. *Medical Journal of Dr. D.Y. Patil University*.2012;5(2):151-3.
20. Euzéby JP. List of bacterial names with standing in nomenclature. *Int. J. Syst. Bacteriol.* 2008;47:590–2.
21. Tomaras A, Dorsey C, Edelmann R., Actis L. “Attachment to and biofilm formation on abiotic surfaces by *A. baumannii*: involvement of a novel chaperone-usher pili assembly system.” *Microbiology.* 2003;149: 3473-84.
22. Sebeny PJ, Riddle MS, Petersen K. *A. baumannii* skin and soft-tissue infection associated with war trauma. *Clin Infect Dis.* 2008; 47:444-9.
23. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, Martin M, et al. *A. baumannii*: an emerging multidrug-resistant pathogen in critical care. *Crit Care Nurse*.2008; 28:15-25.
24. Bayuga S, Zeana C, Sahni J, Della-Latta P, el-Sadr W, Larson E. Prevalence and antimicrobial patterns of *A. baumannii* on hands and nares of hospital personnel and patients: the iceberg phenomenon again. *Heart Lung*.2002; 31:382-90.
25. Howard A, O’Donoghue M, FeeneyA, Sleator RD. *A. baumannii*: an emerging opportunistic pathogen virulence.PMC. 2012;3(3):243-50.
26. Vila J,Marti S, Sanchez-Cespedes J.Porins, efflux pumps and multidrug resistance in *A. baumannii*. *J Antimicrob Chemother.* 2007;59(6):1210-5.
27. Gaddy JA, Tomaras AP,Actis LA. The *A. baumannii* 19606 OmpA Protein Plays a Role in Biofilm Formation on Abiotic Surfaces and in the Interaction of This Pathogen with Eukaryotic Cells. *Infect Immun*.2009;77(8): 3150–60.
28. Choi CH, Lee JS, Lee YC, Park TI, Lee JC. *A. baumannii* invades epithelial cells and outer membrane protein A mediates interactions with epithelial cells. *BMC Microbiology*.2008;8(216):1-11.
29. Seifert H, Strate A,Pulverer G.Nosocomial bacteremia due to *A. baumannii*, clinical features, epidemiology and predictors of mortality. *Medicine*.1995;74:340-9.
30. Taskin G, Ozturk K, Turker T, Ocal N, Cakar M, Ozer S. Assessment of Mortality Risk Factors For Critically Ill Patients With *A. baumannii* Bacteremia With a New Perspective. *Acta Medica Mediterranea*.2016;32;1891-7.
31. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB. Management of Adults With Hospital-acquired and Ventilator – associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis.* 2016;63(5): 61-111.
32. Hidayati. Infeksi bakteri Gram negatif: focus pada *A. baumannii*. *Jurnal Medika kedokteran Indonesia.* 2011;6:1-8.
33. Aspas AM, Sanchez FMG, Colchero FG, Roca SR, Gonzales JAG. Differential characteristics of *A. baumannii* colonization and infection: risk factors, clinical picture, and mortality. *Infect Drug Resist.* 2018;11;861-72.

34. Samawi MSA, Khan FY, Eldeeb Y, Almaslamani M, Alkhal A, Alsoub H, et al. *Acinetobacter* infections among adult patients in Qatar: A 2-Year Hospital-Based study. *Can J Infect Dis Med Microbiol*. 2016;687(3):68-9.
35. Choi CH, Lee EY, Lee YC, Park TI, Kim HJ, Hyun SH, et al. Outer membrane protein 38 of *A. baumannii* localizes to the mitochondria and induces apoptosis of epithelial cells. *Cell Microbiol*. 2005;7(8):1127-38.
36. Fournier PE, Richet H. The Epidemiology and Control of *A. baumannii* in Health Care Facilities. *Health Care Epidemiology*. 2006;42(1):692-9.
37. Chen MZ, Hsueh PR, Lee LN, Yu CJ, Yang PC, Luh KT. Severe community-acquired pneumonia due to *A.baumannii*. *Chest*. 2001;120(4):1072-7.
38. Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittel IM, et al. Treatment of multidrug-resistant *A. baumannii* ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. *Clin Infect Dis*. 2003;36(9):111-18.
39. Cisneros JM, Rodríguez-Bano J. Nosocomial bacteremia due to *A. baumannii*: epidemiology, clinical features and treatment. *Clin Microbiol Infect*. 2002;8:687-93.
40. Rice LB. Challenges in identifying new antimicrobial agents effective for treating infections with *A. baumannii* and *Pseudomonas aeruginosa*. *Clin Infect Dis*. 2006;43(2):100-5.
41. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) *A. baumannii* and *Pseudomonas aeruginosa*. *JMed Microbiol*. 2006;55:1619-29.
42. Fernández-Cuenca F, Martínez-Martínez L, Conejo MC, Ayala JA, Perea EJ, Pascual A. Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of *A. baumannii*. *J Antimicrob Chemother*. 2003;51:565-74.
43. Suryani IG, Gustawan IW. Karakteristik Infeksi Multi Drug-Resistant Organisms di Unit Perawatan Intensif Neonatal RSUP Sanglah. 2018:6-13.
44. Vila J, Ruiz J, Goñi P, Jimenez de Anta T. Quinolone-resistance mutations in the topoisomerase IV *parC* gene of *A. baumannii*. *J Antimicrob Chemother*. 1997;39:757-62.
45. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18:268-81.
46. Prabaker K, Weinstein RA. Trends in antimicrobial resistance in intensive care units in the United States. *Curr Opin Crit Care*. 2011;17:472-79
47. Brusselsaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. *Annals of intensive care*. 2011;1:47.
48. Gaynes JE, McGowan Jr. Temporal changes in prevalence of antimicrobial resistance in 23 U.S. hospitals. *Emerg Infect Dis*. 2002;8:697-701.
49. CDC. Multidrug-resistant organisms in healthcare settings. 2006.[Online] <https://www.cdc.gov/mrsa/pdf/mdroGuideline2006.pdf>. Diakses pada 3 Januari 2019.

50. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. *Clin Infect Dis*. 2008;46:1121–2.
51. Manchanda V, Sanchaita S, Singh NP. Multidrug Resistant *Acinetobacter*. *J Glob Infect Dis*. 2010; 2(3): 291–304.
52. Lee CM, Lim HK, Liu CP, Tseng HK. Treatment of pan-drug resistant *A. baumannii*. *Scandinavian Journal of Infectious Diseases*. 2005;37:195-9.
53. Sugiyono. Metode penelitian Kuantitatif, Kualitatif, dan R&D. Bandung: Alfabeta; 2011:207-9.
54. Kementerian Kesehatan RI. Sistem Kesehatan Nasional. 2009. [Online] <http://www.depkes.go.id/resources/download/pusdatin/profil-kesehatan-indonesia/profil-kesehatan-indonesia-2011.pdf>. Diakses tanggal 29 Januari 2019.
55. Uwingabiye J, Frikh M, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, et al. *Acinetobacter* infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units. *Pan Afr Med J*. 2016;23:1-10.
56. Chopra T, Marchaim D, Johnson PC, Awali RA, Doshi H, Chalana I, et al. Risk factors and outcomes for patients with bloodstream infection due to *A. baumannii* - calcoaceticus complex. *AAC*. 2014;58(8):4630-5.
57. Qiao L, Zhang JS, Mei YN, Zhang HZ, Su CL. Analysis of risk factors on prognosis of *A. baumannii* bloodstream infection. *Clin Proteum Bioinform*. 2016;1(2):42-5.
58. Khurana P, Baliga S, Suchitra SM, Prasanna MP. A rising threat-risk factors and outcomes related to infections with *A. baumannii* species. *Asian J Pharm Clin Res*. 2017;10(3):108-11.
59. Vaze ND, Emery CL, Hamilton RJ, Brooks AD, Joshi SG. Patient demographics and characteristics of infection with carbapenem-resistant *Acinetobacter baumannii* in a teaching hospital from the United States. *Adv Infect Dis* 2013;3(1):10-6
60. Punpanich W, Nithitamsakun N, Treeratweeraphong V, Suntarattiwong P. Risk factors for carbapenem non-susceptibility and mortality in *A. baumannii* bacteremia in children. *Int J Disease*. 2012;(16):811-5.
61. Mansur FJ, Barai L, Karim MM, Haq JA, Fatema K, Faruq MO. Intravascular catheter related infection and antimicrobial susceptibility pattern of isolated bacteria in a tertiary care hospital of Bangladesh. *Indian J Med Microbiol* 2014; 32(1): 68-71.
62. Touré A, Vanhems P, Lombard-Bohas C, Souquet JC, Lauerjat M, Chambrier C. Is diabetes a risk factor for central venous access port-related bloodstream infection in oncological patients? *Eur J Clin Microbiol Infect Dis* 2013; 32: 133-8.
63. Park SY, Choo JW, Kwon SH, Yu SN, Lee EJ, Kim TH, et al. Risk factors for mortality in patients with *A. baumannii* bacteremia. *IC journal*. 2013;45(3):325-30.
64. Rebic V, Masic N, Teskeredzic S, Aljicevic M, Abduzaimovic A, Rebic D. The importance of *Acinetobacter* species in the hospital environment. *Med Arch*. 2018;72(5):330-4.

65. Mangukiya JD, Patel KD, Vegad DD. Study of incidence and risk factors of urinary tract infection in catheterised patients admitted at tertiary care hospital. *Int J Res Med Sci.* 2015;3(12):3808-11.
66. Chang R, Greene MT, Chenoweth CE, Kuhn L, Shuman E, Rogers MA, et al. Epidemiology of hospital-acquired urinary tract-related bloodstream infection at a university hospital. *Infect Control Hosp Epidemiol.* 2011;32(11):1127–9.
67. Zhou H, Yao Y, Zhu B, Ren D, Yang Q, Fu Y, et al. Risk factors for acquisition and mortality of multidrug-resistant *A.baumannii* bacteremia. *Medicine.* 2019;98(13):1-7.
68. Yang S, Yoon HJ, Ki MR. Risk factors for mortality in *Acinetobacter* bacteremia. *Braz J Infect Dis.* 2011;15(5):302-15.
69. Joshi SG, Litake GM, Satpute MG, Telang NV, Ghole VS, Niphadkar KB. Clinical and demographic features of infection caused by *Acinetobacter* species. *Indian J Med Sci.* 2006;60:351–360.
70. Lou T, Mo Q, Wang L, Zhong H, Dong Y, Fan Y. Analysis of prognostic factors and drug resistance of central venous catheter-related bloodstream infection caused by multidrug-resistant *A.baumannii*. *Int J Clin.* 2016;9(4):7303-08.
71. Afroz Z, Jobayer M, Ahmed S, Anwar S, Miah MRA. Central venous catheter-related bloodstream infections (CVC-BSI) in patients of clinically suspected septicemia. *Bangladesh Med Res Counc Bull.* 2015;41:89-94.
72. Sohail M, Rashid A, Aslam B, Waseem M, Shahid M, Akram M, et al. Antimicrobial Susceptibility of *Acinetobacter* Clinical Isolated and Emerging Antibiogram Trends for Nosocomial Infection Management. *Revista da Sociedade Brasileira de Medicina Tropical.* 2016;49(3):300-4.
73. Fishbain J, Peleg AY. Treatment of acinetobacter infections. *CID.* 2010;51(1):79-84.
74. Fysaraki, et al. Incidence, clinical, microbiological features and outcome of bloodstream infections in patients undergoing hemodialysis. *Int J Med.* 2013;10:1632-8.
75. Blanco, et al. Risk factors and outcomes associated with multi-drug resistant *A.baumannii* upon intensive care unit admission. *AAC.* 2018;62(1):1-7.
76. Magira EE, Islam S, Niederman MS. Multi-drug resistant organism infections in a medical ICU: Association to clinical features and impact upon outcome. *Med Intensiva.* 2018;42(4):225-34.
77. Marik PE, Flemmer M, Harrison W. The risk of catheter-related bloodstream infection with femoral venous catheters as compared to subclavian and internal jugular venous catheters: A systematic review of the literature and metaanalysis. *Crit Care Med* 2012; 40: 2479-85.
78. Huang, Mathews AL. Acquisition and clearance of multidrug resistant *A.baumannii* on healthy young adults concurrently burned in a dust explosion in Taiwan: the implication for antimicrobial stewardship. *BMC Infect Dis.* 2017;17:1-9.
79. Conrick-Martin I, Foley M, Roche FM, Fraher MH, Burns KM, Morrison P, et al. Catheter-related infection in Irish intensive care units diagnosed with HELICS criteria: a multi-centre surveillance study. *J Hosp Infect.* 2013; 83: 238-43.

80. Apisarntharak A, Apisarntharak P, Warren DK, Fraser VJ. Is Central Venous Catheter Tips' Colonization with Multidrug-Resistant *A.baumannii* a Predictor for Bacteremia?. Clin Infect Dis.2011;52(8):1080-2.
81. Kalanuria AA, Zai W, Mirski M. Ventilator-associated pneumonia in the ICU. Crit Care. 2014;18(2):1-8.
82. Djeribi, R., Bouchloukh, W., Jouenne, T., and Mena, B. Characterization of bacterial biofilms formed on urinary catheters. J Infect Control. 2012;40:854–9.
83. Ekinci F, Bayram N, Devrim I, Apa H, Gulfidan G, Gunay I. Estimating risk factors for acinetobacter bacteremia in pediatric settings. Braz J Infect Dis.2013;17(4):505-6.
84. Kurniawati AFS, Satyabakti P, Arbianti N. Perbedaan risiko multidrug resistance organisms (MDROS) menurut faktor risiko dan kepatuhan hand hygiene. JBE.2015;3(3):277-89.
85. Falcone M, Russo A, Lacovelli A, Restuccia G, Ceccarelli G, Farcomeni A, et al. Predictors of outcome in ICU patients with septic shock due to multidrug-resistant *A.baumannii* or *klebsiella pneumoniae* carbapenemase-producing *K. Pneumoniae* in intensive care unit patients. AAC. 2018;62(8):1-12.

